It's How Medicine Should Be®

Physician Profile


call (888) 352-RUSH for help arranging an appointment

Ross A. Abrams, MD

  • Oncology, Radiation
  • Hematology
  • Oncology, Medical
  • Internal Medicine
Board Certification:
  • Radiation Oncology
  • Hematology
  • Medical Oncology
  • Internal Medicine
Faculty Rank: Professor
Medical or Graduate Education: University of Pennsylvania School of Medicine
Residency: Duke University Health System - Internal Medicine
  Hospital of the University of Pennsylvania - Internal Medicine
Fellowship: Hospital of the University of Pennsylvania - Hematology/Oncology
  National Cancer Institute - Oncology
  Medical College of Wisconsin Affiliated Hospitals - Radiation Oncology
Clinical Expertise:
  • Bone cancer (bone sarcoma)
  • Carcinoid tumor
  • Hepatobiliary cancer
  • Hodgkin lymphoma
  • Non-Hodgkin lymphoma
  • Pancreatic cancer
  • Skin cancer
  • Soft tissue sarcoma
  • Stomach cancer
  • Total body irradiation
Research Interests:
  • Cooperative group oncology research (Radiation Therapy Oncology Group)
Languages Spoken:
  • Hebrew
Google Map
Google Map

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to Listings go back five years.

  1. Retroperitoneal Sarcoma (RPS) High Risk Gross Tumor Volume Boost (HR GTV Boost) Contour Delineation Agreement Among NRG Sarcoma Radiation and Surgical Oncologists.
    Baldini EH, Bosch W, Kane JM, Abrams RA, Salerno KE, Deville C, Raut CP, Petersen IA, Chen YL, Mullen JT, Millikan KW, Karakousis G, Kendrick ML, DeLaney TF, Wang D
    Ann. Surg. Oncol.
    2015 Sep
  2. Treatment Guidelines for Preoperative Radiation Therapy for Retroperitoneal Sarcoma: Preliminary Consensus of an International Expert Panel.
    Baldini EH, Wang D, Haas RL, Catton CN, Indelicato DJ, Kirsch DG, Roberge D, Salerno K, Deville C, Guadagnolo BA, O'Sullivan B, Petersen IA, Le Pechoux C, Abrams RA, DeLaney TF
    Int. J. Radiat. Oncol. Biol. Phys.
    2015 Jul 1
  3. Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the Pancreas.
    Ben-Josef E, George A, Regine WF, Abrams R, Morgan M, Thomas D, Schaefer PL, DiPetrillo TA, Fromm M, Small W, Narayan S, Winter K, Griffith KA, Guha C, Williams TM
    Clin. Cancer Res.
    2015 Aug 3
  4. Comparison of investigator-delineated gross tumor volumes and quality assurance in pancreatic cancer: Analysis of the pretrial benchmark case for the SCALOP trial.
    Fokas E, Clifford C, Spezi E, Joseph G, Branagan J, Hurt C, Nixon L, Abrams R, Staffurth J, Mukherjee S
    Radiother Oncol
    2015 Aug 29
  5. Retroperitoneal Sarcoma Target Volume and Organ at Risk Contour Delineation Agreement Among NRG Sarcoma Radiation Oncologists.
    Baldini EH, Abrams RA, Bosch W, Roberge D, Haas RL, Catton CN, Indelicato DJ, Olsen JR, Deville C, Chen YL, Finkelstein SE, DeLaney TF, Wang D
    Int. J. Radiat. Oncol. Biol. Phys.
    2015 Aug 1
  6. Radiosensitizing effect of anti-HER2/neu agents: Report of 2 cases and review of the literature.
    Katz DA, Abrams RA, Sclamberg JS, Usha L
    Pract Radiat Oncol
    2014 Oct 25
  7. Radiotherapy for soft tissue sarcoma: 50 years of change and improvement.
    Wang D, Abrams RA
    Am Soc Clin Oncol Educ Book
  8. Agreement Among RTOG Sarcoma Radiation Oncologists in Contouring Suspicious Peritumoral Edema for Preoperative Radiation Therapy of Soft Tissue Sarcoma of the Extremity.
    Bahig H, Roberge D, Bosch W, Levin W, Petersen I, Haddock M, Freeman C, Delaney TF, Abrams RA, Indelicato DJ, Baldini EH, Hitchcock Y, Kirsch DG, Kozak KR, Wolfson A, Wang D.
    Int J Radiat Oncol Biol Phys. 2013
    2013 Mar 5. doi:pii: S0360-3016(13)00128-4. 10.1016/j.ijrobp.2013.01.032. [Epub ahead of print]
  9. Radiation therapy in primary bone tumors for young patients.
    Dandekar V, Abrams R, Kent PM
    Curr Probl Cancer
    2013 Jul-Aug
  10. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
    Mukherjee S, Hurt CN, Bridgewater J, Falk S, Cummins S, Wasan H, Crosby T, Jephcott C, Roy R, Radhakrishna G, McDonald A, Ray R, Joseph G, Staffurth J, Abrams RA, Griffiths G, Maughan T.
    Lancet Oncol. 2013
    2013 Apr
    14(4):317-26. doi: 10.1016/S1470-2045(13)70021-4. Epub 2013 Mar 6.
  11. Evolving concepts regarding the use of radiotherapy in the adjuvant management of periampullary pancreatic adenocarcinoma.
    Abrams RA.
    Cancer J. 2012
    2012 Nov-Dec
    18(6):624-32. doi: 10.1097/PPO.0b013e3182758c84.
  12. Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 ≤90 U/mL and comparison to the CONKO-001 trial.
    Berger AC, Winter K, Hoffman JP, Regine WF, Abrams RA, Safran H, Freedman GM, Benson AB 3rd, Macdonald J, Willett CG.
    Int J Radiat Oncol Biol Phys. 2012
    2012 Nov 1
    84(3):e291-7. doi: 10.1016/j.ijrobp.2012.04.035. Epub 2012 Jun 9.
  13. Radiation Therapy Oncology Group consensus panel guidelines for the delineation of the clinical target volume in the postoperative treatment of pancreatic head cancer.
    Goodman KA, Regine WF, Dawson LA, Ben-Josef E, Haustermans K, Bosch WR, Turian J, Abrams RA.
    Int J Radiat Oncol Biol Phys. 2012
    2012 Jul 1
    83(3):901-8. doi: 10.1016/j.ijrobp.2012.01.022. Epub 2012 Apr 5.
  14. Successful treatment of anal carcinoma with Paclitaxel, Cisplatin, and radiotherapy in a patient who developed a coronary syndrome from 5-fu.
    Garg S, Abrams RA, Leslie WT.
    Gastrointest Cancer Res. 2012
    2012 Jul
    5(4):135-6. No abstract available.
  15. Supportive Care Considerations During Concurrent Chemoradiotherapy for Pancreatic Adenocarcinoma: Lessons Learned From Clinical Experience.
    Wang-Gillam A, Abrams RA, Posner MC, Pisters PW, Picozzi VJ.
    Am J Clin Oncol. 2012
    2012 Jan 10. [Epub ahead of print]
  16. Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas.
    Abrams RA, Winter KA, Regine WF, Safran H, Hoffman JP, Lustig R, Konski AA, Benson AB, Macdonald JS, Rich TA, Willett CG.
    Int J Radiat Oncol Biol Phys. 2012
    2012 Feb 1
    82(2):809-16. doi: 10.1016/j.ijrobp.2010.11.039. Epub 2011 Feb 1.
  17. Prognostic Significance of Carbohydrate Antigen 19-9 in Unresectable Locally Advanced Pancreatic Cancer Treated With Dose-Escalated Intensity Modulated Radiation Therapy and Concurrent Full-Dose Gemcitabine: Analysis of a Prospective Phase 1/2 Dose Escalation Study.
    Vainshtein JM, Schipper M, Zalupski MM, Lawrence TS, Abrams R, Francis IR, Khan G, Leslie W, Ben-Josef E.
    Int J Radiat Oncol Biol Phys. 2012
    2012 Dec 19. doi:pii: S0360-3016(12)03817-5. 10.1016/j.ijrobp.2012.11.020. [Epub ahead of print]
  18. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.
    Ben-Josef E, Schipper M, Francis IR, Hadley S, Ten-Haken R, Lawrence T, Normolle D, Simeone DM, Sonnenday C, Abrams R, Leslie W, Khan G, Zalupski MM.
    Int J Radiat Oncol Biol Phys. 2012
    2012 Dec 1
    84(5):1166-71. doi: 10.1016/j.ijrobp.2012.02.051. Epub 2012 Apr 27.
  19. Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations.
    Huguet F, Goodman KA, Azria D, Racadot S, Abrams RA.
    Int J Radiat Oncol Biol Phys. 2012
    2012 Aug 1
    83(5):1355-64. doi: 10.1016/j.ijrobp.2011.11.050.
  20. Radiotherapy in the adjuvant management of pancreatic adenocarcinoma: is it helpful?
    Abrams RA.
    Expert Rev Gastroenterol Hepatol. 2012
    2012 Apr
    6(2):149-61. doi: 10.1586/egh.12.3. Review.
  21. A simplified technique for delivering total body irradiation (TBI) with improved dose homogeneity.
    Yao R, Bernard D, Turian J, Abrams RA, Sensakovic W, Fung HC, Chu JC.
    Med Phys. 2012
    2012 Apr
    39(4):2239-48. doi: 10.1118/1.3697526.
  22. Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51.
    Daniels TB, Brown PD, Felten SJ, Wu W, Buckner JC, Arusell RM, Curran WJ, Abrams RA, Schiff D, Shaw EG.
    Int J Radiat Oncol Biol Phys. 2011
    2011 Sep 1
    81(1):218-24. doi: 10.1016/j.ijrobp.2010.05.003. Epub 2011 May 5.
  23. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival.
    Gielda BT, Mehta P, Khan A, Marsh JC, Zusag TW, Warren WH, Fidler MJ, Abrams RA, Bonomi P, Liptay M, Faber LP.
    Int J Radiat Oncol Biol Phys. 2011
    2011 Nov 15
    81(4):985-91. doi: 10.1016/j.ijrobp.2010.06.059. Epub 2010 Oct 6.
  24. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
    Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Rich TA, Willett CG.
    Ann Surg Oncol. 2011
    2011 May
    18(5):1319-26. doi: 10.1245/s10434-011-1630-6. Epub 2011 Mar 10.
  25. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients.
    Gielda BT, Marsh JC, Zusag TW, Faber LP, Liptay M, Basu S, Warren WH, Fidler MJ, Batus M, Abrams RA, Bonomi P.
    J Thorac Oncol. 2011
    2011 Jun
    6(6):1079-86. doi: 10.1097/JTO.0b013e3182199a7c.
  26. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial.
    Katz MH, Merchant NB, Brower S, Branda M, Posner MC, William Traverso L, Abrams RA, Picozzi VJ, Pisters PW; American College of Surgeons Oncology Group.
    Ann Surg Oncol. 2011
    2011 Feb
    18(2):337-44. doi: 10.1245/s10434-010-1282-y. Epub 2010 Sep 1.
  27. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation.
    Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, Sugar E, Piantadosi S, Cameron JL, Solt S, Onners B, Tartakovsky I, Choi M, Sharma R, Illei PB, Hruban RH, Abrams RA, Le D, Jaffee E, Laheru D.
    Ann Surg. 2011
    2011 Feb
    253(2):328-35. doi: 10.1097/SLA.0b013e3181fd271c.
  28. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031.
    Picozzi VJ, Abrams RA, Decker PA, Traverso W, O'Reilly EM, Greeno E, Martin RC, Wilfong LS, Rothenberg ML, Posner MC, Pisters PW; American College of Surgeons Oncology Group.
    Ann Oncol. 2011
    2011 Feb
    22(2):348-54. doi: 10.1093/annonc/mdq384. Epub 2010 Jul 29.
  29. The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704.
    Showalter TN, Winter KA, Berger AC, Regine WF, Abrams RA, Safran H, Hoffman JP, Benson AB, MacDonald JS, Willett CG.
    Int J Radiat Oncol Biol Phys. 2011
    2011 Dec 1
    81(5):1328-35. doi: 10.1016/j.ijrobp.2010.07.1993. Epub 2010 Oct 8.
  30. Radiation therapy for heterotopic ossification prophylaxis afer high-risk elbow surgery.
    Strauss JB, Wysocki RW, Shah A, Chen SS, Shah AP, Abrams RA, Cohen MS.
    Am J Orthop (Belle Mead NJ). 2011
    2011 Aug
  31. Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma.
    Kasamon YL, Jones RJ, Brodsky RA, Fuchs EJ, Matsui W, Luznik L, Powell JD, Blackford AL, Goodrich A, Gocke CD, Abrams RA, Ambinder RF, Flinn IW.
    Ann Oncol. 2010
    2010 Jun
    21(6):1203-10. doi: 10.1093/annonc/mdp484. Epub 2009 Oct 30.
  32. Variation in post-surgical lumpectomy cavity volume with delay in initiation of breast irradiation because of chemotherapy.
    Strauss JB, Gielda BT, Chen SS, Shah AP, Abrams RA, Griem KL.
    Int J Radiat Oncol Biol Phys. 2010
    2010 Jul 1
    77(3):831-5. doi: 10.1016/j.ijrobp.2009.05.061. Epub 2009 Sep 30.
  33. Intracranial metastatic disease spares the limbic circuit: a review of 697 metastatic lesions in 107 patients.
    Marsh JC, Herskovic AM, Gielda BT, Hughes FF, Hoeppner T, Turian J, Abrams RA.
    Int J Radiat Oncol Biol Phys. 2010
    2010 Feb 1
    76(2):504-12. doi: 10.1016/j.ijrobp.2009.02.038.
  34. Review and commentary on the role of radiation therapy in the adjuvant management of pancreatic cancer.
    Shah AP, Strauss JB, Abrams RA.
    Am J Clin Oncol. 2010
    2010 Feb
    33(1):101-6. doi: 10.1097/COC.0b013e31819171b9. Review.
  35. A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma: A Phase II Trial of Safety, Efficacy, and Immune Activation
    Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, Sugar E, Piantadosi S, Cameron JL, Solt S, Onners B, Tartakovsky I, Choi M, Sharma R, Illei PB, Hruban RH, Abrams RA, Le D, Jaffee E, Laheru D
    Ann Surg
    2010 Dec 17
  36. Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis.
    Liggett T, Melnikov A, Yi QL, Replogle C, Brand R, Kaul K, Talamonti M, Abrams RA, Levenson V.
    Cancer. 2010
    2010 Apr 1
    116(7):1674-80. doi: 10.1002/cncr.24893.
  37. Cognitive Sparing during the Administration of Whole Brain Radiotherapy and Prophylactic Cranial Irradiation: Current Concepts and Approaches.
    Marsh JC, Gielda BT, Herskovic AM, Abrams RA.
    J Oncol. 2010
    2010:198208. doi: 10.1155/2010/198208. Epub 2010 Jun 27.
  38. Evaluation of four volume-based image registration algorithms.
    Zhang Y, Chu JC, Hsi W, Khan AJ, Mehta PS, Bernard DB, Abrams RA.
    Med Dosim. 2009
    2009 Winter
    34(4):317-22. doi: 10.1016/j.meddos.2008.12.004. Epub 2009 Feb 5.
  39. Application of holographic display in radiotherapy treatment planning II: a multi-institutional study.
    Chu JCh, Gong X, Cai Y, Kirk MC, Zusag TW, Shott S, Rivard MJ, Melhus CS, Cardarelli G, Hurley A, Hepel JT, Napoli J, Stutsman S, Abrams RA.
    J Appl Clin Med Phys. 2009
    2009 May 28
  40. Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas.
    Myerson RJ, Garofalo MC, El Naqa I, Abrams RA, Apte A, Bosch WR, Das P, Gunderson LL, Hong TS, Kim JJ, Willett CG, Kachnic LA.
    Int J Radiat Oncol Biol Phys. 2009
    2009 Jul 1
    74(3):824-30. doi: 10.1016/j.ijrobp.2008.08.070. Epub 2008 Dec 29.
  41. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement.
    Abrams RA, Lowy AM, O'Reilly EM, Wolff RA, Picozzi VJ, Pisters PW.
    Ann Surg Oncol. 2009
    2009 Jul
    16(7):1751-6. doi: 10.1245/s10434-009-0413-9. Epub 2009 Apr 24. No abstract available.
  42. Cholangiocarcinoma--what level of evidence should we have?
    Abrams RA.
    Int J Radiat Oncol Biol Phys. 2009
    2009 Jan 1
    73(1):1-2. doi: 10.1016/j.ijrobp.2008.08.041. No abstract available.
  43. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
    Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE, Dicker AP, Mackey JR.
    Gastroenterology. 2009
    2009 Jan
    136(1):187-95. doi: 10.1053/j.gastro.2008.09.067. Epub 2008 Oct 7.
  44. Management of a patient with borderline resectable pancreatic cancer. Case report and review.
    Shah AP, Strauss JB, Leslie WT, Shah A, Mahon B, Abrams RA.
    Oncology (Williston Park). 2008
    2008 Nov 30
    22(13):1524-9. Review.
  45. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
    Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, Haddock MG, Schaefer P, Willett CG, Rich TA.
    JAMA. 2008
    2008 Mar 5
    299(9):1019-26. doi: 10.1001/jama.299.9.1019. Erratum in: JAMA. 2008 Apr 23/30;299(16):1902.
  46. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital.
    Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, Robinson R, Laheru DA, Jaffee E, Hruban RH, Campbell KA, Wolfgang CL, Asrari F, Donehower R, Hidalgo M, Diaz LA Jr, Yeo C, Cameron JL, Schulick RD, Abrams R.
    J Clin Oncol. 2008
    2008 Jul 20
    26(21):3503-10. doi: 10.1200/JCO.2007.15.8469.
  47. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704.
    Berger AC, Garcia M Jr, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson AB 3rd, MacDonald J, Willett CG.
    J Clin Oncol. 2008
    2008 Dec 20
    26(36):5918-22. doi: 10.1200/JCO.2008.18.6288. Epub 2008 Nov 24.
  • (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
  • View Transcript